Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
about
Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic optionsIn vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147Cytotoxic efficacy of a novel dinuclear platinum(II) complex used with anti-MUC1 in human breast cancer cells.CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.Nanoparticle formulation of ormeloxifene for pancreatic cancerPolydopamine-enabled surface functionalization of gold nanorods for cancer cell-targeted imaging and photothermal therapyThe combined treatment with novel platinum(II) complex and anti-MUC1 increases apoptotic response in MDA-MB-231 breast cancer cells.MUC1 and metastatic cancer: expression, function and therapeutic targeting.Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach.Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy.The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy.A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer.
P2860
Q26748666-D9E38BB4-EDD2-4C21-86EF-80710F100C96Q28482047-46FA6C50-D809-4629-B06F-96D2C1629758Q33741303-3DF984D4-30DA-48C6-A4F8-8EC75E4C49A6Q35116847-F76A6102-506B-4DAF-90D7-E2C03BFBD655Q35517037-3767C280-3C4D-42C0-BDCF-688196A2F270Q36489491-9374E053-95F2-4DEC-81DB-67F0B527F309Q36621615-8FDC49B8-4E0A-41D3-8742-D659DA09A059Q37636939-E4A01F1B-1861-463C-9BD8-1EC90562383EQ37657753-A4653D99-1D82-4151-B6ED-326FB7F66A8CQ37687556-60967CA3-B29D-471C-A5AB-58A37D1B4DF8Q38100999-19584236-A75A-4E5D-831F-800AAE8FB02FQ38142315-68CA3D66-0D96-4147-82E6-F02B2CAE0789Q47104633-4888EF10-A8CD-474D-8919-21B918892C4A
P2860
Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Anti-MUC1 monoclonal antibody ...... in vivo ovarian cancer model.
@ast
Anti-MUC1 monoclonal antibody ...... in vivo ovarian cancer model.
@en
Anti-MUC1 monoclonal antibody ...... in vivo ovarian cancer model.
@nl
type
label
Anti-MUC1 monoclonal antibody ...... in vivo ovarian cancer model.
@ast
Anti-MUC1 monoclonal antibody ...... in vivo ovarian cancer model.
@en
Anti-MUC1 monoclonal antibody ...... in vivo ovarian cancer model.
@nl
prefLabel
Anti-MUC1 monoclonal antibody ...... in vivo ovarian cancer model.
@ast
Anti-MUC1 monoclonal antibody ...... in vivo ovarian cancer model.
@en
Anti-MUC1 monoclonal antibody ...... in vivo ovarian cancer model.
@nl
P2093
P2860
P1433
P1476
Anti-MUC1 monoclonal antibody ...... n in vivo ovarian cancer model
@en
P2093
Hongmin Chen
Hongtu Chao
Jingli Hao
John H Kearsley
Julia Beretov
Mohammad H Pourgholami
P2860
P304
P356
10.1371/JOURNAL.PONE.0024405
P407
P577
2011-09-09T00:00:00Z